Stock events for Sutro Biopharma, Inc. (STRO)
Sutro Biopharma's stock has been impacted by a reverse stock split, stock offerings, clinical trial progress, analyst upgrades, investor conferences, and financial results. A 1-for-10 reverse stock split was implemented in December 2025 to regain compliance with Nasdaq's minimum bid price requirement. In February 2026, a $110.0 million underwritten offering of common stock was priced to extend its cash runway. The company announced the dosing of the first patient cohort in its Phase 1 trial of STRO-004 in December 2025. Analyst upgrades from Market Perform to Market Outperform were given in January 2026. The company has participated in several investor and scientific conferences and reported its Q3 2025 financial results in November 2025.
Demand Seasonality affecting Sutro Biopharma, Inc.’s stock price
Sutro Biopharma, Inc. does not experience demand seasonality. The demand for Sutro's offerings is driven by the successful progression of its drug candidates through clinical trials, positive regulatory outcomes, and the establishment of strategic collaborations. The company's revenue is largely influenced by collaboration agreements and research and development milestones rather than direct product sales to end-users.
Overview of Sutro Biopharma, Inc.’s business
Sutro Biopharma, Inc. is a clinical-stage oncology company focused on discovering, developing, and manufacturing next-generation biopharmaceutical products for cancer and autoimmune disorders. They utilize their XpressCF and XpressCF+ platforms to engineer antibody-drug conjugates (ADCs) to improve drug exposure and minimize side effects. Sutro's pipeline includes STRO-001, STRO-002, STRO-004, STRO-006 and STRO-227, each in various stages of clinical trials or preclinical development. The company collaborates with partners like Astellas Pharma Inc., Tasly Biopharmaceuticals Co., Ltd., and Ipsen.
STRO’s Geographic footprint
Sutro Biopharma, Inc. is headquartered in South San Francisco, California. The company previously had a manufacturing-support facility in San Carlos, California, but it was winded down in March 2025.
STRO Corporate Image Assessment
Sutro Biopharma's brand reputation has been shaped by a strategic pivot and restructuring in March 2025. The deprioritization of luveltamab tazevibulin and workforce reduction negatively impacted reputation. The company's focus on next-generation ADCs could positively impact its scientific reputation. An analyst upgrade in January 2026 suggests positive sentiment regarding the company's future prospects.
Ownership
Sutro Biopharma, Inc. has a significant institutional ownership presence, with 59 institutional owners and shareholders holding 5,308,512 shares as of February 26, 2026. Major institutional shareholders include Affinity Asset Advisors, LLC, Kynam Capital Management, LP, Millennium Management Llc, Vanguard Group Inc, Acadian Asset Management Llc, Velan Capital Investment Management LP, Vestal Point Capital, LP, Balyasny Asset Management Llc, Samsara BioCapital, LLC, and Adage Capital Partners Gp, L.l.c. Other notable institutional investors include RA Capital Management, L.P. and BlackRock, Inc. Individual insiders hold approximately 0.88% of the shares, with Peter Kolchinsky owning the most shares among individual investors.
